Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
Authors:
- Alexandra A Abu-ShmaisAAAlexandra A Abu-Shmais
- Rose J. MillerRMRose J. Miller
- Alexis K. JankeAJAlexis K. Janke
- Rachael M. WoltersRWRachael M. Wolters
- Clinton M. HoltCHClinton M. Holt
- Nagarajan RajuNRNagarajan Raju
- Robert H. CarnahanRCRobert H. Carnahan
- James E CroweJCJames E Crowe
- Jarrod J. MousaJarrod J. Mousa
- Ivelin S. GeorgievIGIvelin S. Georgiev
- 15 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (9) , 1450-1456
Abstract
Human parainfluenza virus 3 (HPIV3) is a widespread pathogen causing severe and lethal respiratory illness in at-risk populations. Effective countermeasures are in various stages of development; however, licensed therapeutic and prophylactic options are not available. The fusion glycoprotein (HPIV3 F), responsible for facilitating viral entry into host cells, is a major target of neutralizing Abs that inhibit infection. Although several neutralizing Abs against a small number of HPIV3 F epitopes have been identified to date, relatively little is known about the Ab response to HPIV3 compared with other pathogens, such as influenza virus and SARS-CoV-2. In this study, we aimed to characterize a set of HPIV3-specific Abs identified in multiple individuals for genetic signatures, epitope specificity, neutralization potential, and publicness. We identified 12 potently neutralizing Abs targeting three nonoverlapping epitopes on HPIV3 F. Among these, six Abs identified from two different individuals used Ig heavy variable gene IGHV 5-51, with five of the six Abs targeting the same epitope. However, despite the use of the same H chain variable (VH) gene, these Abs used multiple different L chain variable genes (VL) and diverse H chain CDR 3 (CDRH3) sequences. Together, these results provide further information about the genetic and functional characteristics of HPIV3-neutralizing Abs and suggest the existence of a reproducible VH-dependent Ab response associated with VL and CDRH3 promiscuity. Understanding sites of HPIV3 F vulnerability and the genetic and molecular characteristics of Abs targeting these sites will help guide efforts for effective vaccine and therapeutic development.Keywords
Funding Information
- G. Harold and Leila Y. Mathers Foundation (MF-2107-01851)
- Foundation for the National Institutes of Health (R01AI175245)
- Foundation for the National Institutes of Health (5T32AI112541-07)
- Foundation for the National Institutes of Health (1K01OD036063-01)
This publication has 25 references indexed in Scilit:
- SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypesCell Reports Medicine, 2023
- Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypesCell Reports, 2023
- High-Throughput Mapping of B Cell Receptor Sequences to Antigen SpecificityCell, 2019
- Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 InfectionCell Host & Microbe, 2018
- Paramyxovirus Glycoproteins and the Membrane Fusion ProcessCurrent Clinical Microbiology Reports, 2016
- Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesCell, 2016
- Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic reviewCancer Letters, 2016
- Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenVaccine, 2013
- Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant RecipientsTransplantation and Cellular Therapy, 2010
- Parainfluenza Virus Infection of Young Children: Estimates of the Population-Based Burden of HospitalizationThe Journal of Pediatrics, 2009